Semaglutide

Semaglutide

Learn about

Semaglutide

Semaglutide is a GLP-1 receptor agonist medication used for medically supervised weight loss. Originally developed to manage blood sugar in type 2 diabetes, it's now FDA-approved specifically for chronic weight management in adults with obesity or excess weight and related health conditions. Semaglutide works by mimicking a hormone that regulates appetite and food intake, helping patients feel fuller longer and reduce overall calorie consumption. At Elite Medical Solutions, Semaglutide is administered under the medical supervision of Sarina Howard, PA-C, as part of a comprehensive weight loss program.

Real, Medically Supervised Weight Loss

At Elite Medical Solutions, Semaglutide is prescribed and monitored by Sarina Howard, PA-C, as part of an individualized weight loss plan. Clinical trials show patients average 15% or more total body weight loss over 68 weeks when combined with lifestyle changes.

Clinically Proven Results:

Semaglutide has been shown in clinical trials to produce average weight loss of 15% or more of total body weight when combined with diet and lifestyle changes.

Appetite Regulation:

Semaglutide mimics the GLP-1 hormone, which signals fullness to the brain and slows gastric emptying, helping reduce hunger and portion sizes naturally.

Weekly Injection:

Semaglutide is administered as a simple weekly injection, making it a convenient option that fits into your regular routine.

Medical Supervision:

Your treatment is monitored by Sarina Howard, PA-C, with regular check-ins to adjust dosing and track progress safely.

Metabolic Health Benefits:

Beyond weight loss, Semaglutide has been shown to improve blood sugar control and reduce cardiovascular risk factors in appropriate candidates..

Individualized Dosing:

Treatment starts at a low dose and is gradually increased under medical supervision to minimize side effects while maximizing results.

Frequently Asked Questions

Clinical trials show an average total body weight loss of 15% or more over 68 weeks when combined with diet and exercise. Individual results vary based on starting weight, adherence, and metabolic factors

Semaglutide is given as a once-weekly subcutaneous injection. Your provider will teach you the proper technique, and most patients self-administer at home after initial training.

Candidates typically have a BMI of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher. A consultation with Sarina Howard PA-C will confirm eligibility.

The most common side effects are nausea, diarrhea, and constipation, especially during dose escalation. These typically improve over time. Your provider will monitor you throughout treatment.

Schedule A Consultation

Contact us to schedule a consultation and find out more about this procedure.

Featured Navigation

Semaglutide
Tirzepatide